Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

Clinical & Translational Oncology ◽

10.1007/s12094-017-1797-9 ◽

2017 ◽

Vol 20 (7) ◽

pp. 862-869 ◽

Author(s):

I. Blancas ◽

M. Fontanillas ◽

V. Conde ◽

J. Lao ◽

E. Martínez ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Practice ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Routine Clinical Practice ◽

Advanced Breast

Download Full-text

Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

Clinical & Translational Oncology ◽

10.1007/s12094-018-1956-7 ◽

2018 ◽

Vol 20 (12) ◽

pp. 1631-1632

Author(s):

I. Blancas ◽

M. Fontanillas ◽

V. Conde ◽

J. Lao ◽

E. Martínez ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Practice ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Routine Clinical Practice ◽

Advanced Breast

Download Full-text

Abstract P4-22-20: Efficacy and safety of everolimus plus exemestane in HR+, HER2– advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2ndinterim analysis from STEPAUT

10.1158/1538-7445.sabcs16-p4-22-20 ◽

2017 ◽

Author(s):

GG Steger ◽

R Bartsch ◽

G Pfeiler ◽

E Petru ◽

R Greil ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Practice ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Routine Clinical Practice ◽

Advanced Breast ◽

Efficacy And Safety

Download Full-text

58P Detection of PIK3CA mutations in plasma ctDNA by Crystal Digital PCR for the selection of alpelisib treatment in routine clinical practice in advanced breast cancer patients

Annals of Oncology ◽

10.1016/j.annonc.2020.03.192 ◽

2020 ◽

Vol 31 ◽

pp. S35

Author(s):

T. de La Motte Rouge ◽

F. Le Du ◽

J. Corne ◽

F. Godey ◽

H. Bourien ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Practice ◽

Advanced Breast Cancer ◽

Cancer Patients ◽

Digital Pcr ◽

Routine Clinical Practice ◽

Advanced Breast ◽

Breast Cancer Patients ◽

Pik3ca Mutations ◽

Download Full-text

Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT

10.1016/j.breast.2020.01.035 ◽

2020 ◽

Vol 50 ◽

pp. 64-70

Author(s):

Guenther G. Steger ◽

Daniel Egle ◽

Rupert Bartsch ◽

Georg Pfeiler ◽

Edgar Petru ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Practice ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Routine Clinical Practice ◽

Advanced Breast ◽

Efficacy And Safety ◽

Interventional Study

Download Full-text

Abstract P6-18-08: Everolimus + exemestane for HR+ advanced breast cancer in routine clinical practice- Final results from the non-interventional trial, BRAWO

10.1158/1538-7445.sabcs18-p6-18-08 ◽

2019 ◽

Author(s):

D Lüftner ◽

F Schuetz ◽

A Schneeweiss ◽

E-M Grischke ◽

W Bloch ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Practice ◽

Advanced Breast Cancer ◽

Routine Clinical Practice ◽

Advanced Breast ◽

Interventional Trial

Download Full-text

Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0036-1592812 ◽

2016 ◽

Vol 76 (10) ◽

Author(s):

EM Grischke ◽

A Nusch ◽

N Marschner ◽

W Abenhardt ◽

J Wilke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Disease ◽

Advanced Breast ◽

Prior Therapy ◽

Hormone Receptor Positive

Download Full-text

Faculty Opinions recommendation of Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2- Advanced Breast Cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.738775672.793581181 ◽

2020 ◽

Author(s):

Jason S Carroll

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Dose Escalation ◽

Advanced Breast ◽

Download Full-text

Clinical Trial of Letrozole (femara) versus Aminoglutethimide in Postmenopausal Women with Advanced Breast Cancer

The Chinese-German Journal of Clinical Oncology ◽

10.1007/s10330-005-0387-4 ◽

2005 ◽

Vol 4 (6) ◽

pp. 338-340

Author(s):

Xiaoqing LIU ◽

Santai SONG ◽

Zefei JIANG ◽

Weilian LI ◽

Weixia WANG ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Advanced Breast

Download Full-text

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Annals of Oncology ◽

10.1093/annonc/mdu009 ◽

2014 ◽

Vol 25 (4) ◽

pp. 808-815 ◽

Author(s):

H.S. Rugo ◽

K.I. Pritchard ◽

M. Gnant ◽

S. Noguchi ◽

M. Piccart ◽

...

Keyword(s):

Breast Cancer ◽

Adverse Events ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Time Course ◽

Advanced Breast ◽

Hormone Receptor Positive

Download Full-text

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Journal of Bone Oncology ◽

10.1016/j.jbo.2018.09.010 ◽

2019 ◽

Vol 14 ◽

pp. 100199 ◽

Author(s):

Peyman Hadji ◽

Oliver Stoetzer ◽

Thomas Decker ◽

Christian M. Kurbacher ◽

Frederik Marmé ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Bone Health ◽

Hormone Receptor ◽

Mammalian Target Of Rapamycin ◽

Advanced Breast ◽

Hormone Receptor Positive ◽

Download Full-text